close

Enter

Log in using OpenID

Sirolimus Market

embed
Sirolimus is a macrolide compound also known as rapamycin, which is a potent immunosuppressant and shows both antifungal and antineoplastic properties.
Sirolimus Market - Size, Share, and Opportunity
Analysis, 2019-2026.
Sirolimus
is
a
macrolide
compound
also
known
as
rapamycin,
which
is
a
potent
immunosuppressant and shows both antifungal and antineoplastic properties. It works by
weakening the immune system, and helps your body to accept the new organ, so in this
manner it helps in preventing rejection of any organs after transplant. Sirolimus is also used to
coat coronary stents, and prophylaxis of organ transplant rejection in patients receiving renal
transplants, and for treating Lymphangioleiomyomatosis (lung disease).
Request PDF Brochure Of Research Report:
https://www.coherentmarketinsights.com/insight/request-pdf/2842
Global Sirolimus Market Drivers
Approvals for generic versions of Rapamune (a branded sirolimus formulation) for preventing
organ transplant rejection is expected to drive the global sirolimus market growth. For instance,
in January 2019, Novitium Pharma LLC. received the final approval for its abbreviated new
drug application (ANDA) from the U.S. FDA to market a generic version of an oral solution of
Rapamune 1mg/ml manufactured by PF Prism CV. In October 2014, Dr. Reddys Laboratories
Ltd., received the final approval for its abbreviated new drug application (ANDA) from the U.S,
FDA to market a generic version of Rapamune tablet dosage (1mg). Thus, approvals of sirolimus
products by regulatory authorities to manage (or prevent) organ transplant rejection is expected
to drive growth of the global sirolimus market. Factors such as rising incidence of kidney
diseases has led to an increase in the number of kidney transplants. Furthermore, increasing
prevalence of lifestyle-related disorders, improvement of healthcare infrastructure due to
increasing healthcare spending is expected to support global sirolimus market growth over the
forecast period. According to the National Kidney Foundation, in 2014, around 17,107 kidney
transplants took place in the U.S., among which, 5,537 kidneys were from living donors, and
11,570 kidneys were from deceased donors.
Report includes chapters which deeply display the following deliverable about industry :
• Sirolimus Market Research Objective and Assumption
• Sirolimus Market Purview - Report Description, Executive Summary, and Coherent Opportunity
Map (COM)
• Sirolimus Market Dynamics, Regulations, and Trends Analysis - Market Dynamics, Regulatory
Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals, Value Chain
Analysis, Porter’s Analysis, and PEST Analysis
• Global Sirolimus Market, By Regions
• Sirolimus Market Competition by Manufacturers including Production, Share, Revenue,
Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Sirolimus Market Manufacturers Profiles/Analysis including Company Basic Information,
Manufacturing Base and Its Competitors.
• Sirolimus Market Manufacturing Cost Analysis including Key Raw Materials and Key Suppliers
of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Sirolimus Market Forecast including Production, Consumption, Import and Export Forecast by
Type, Applications and Region.
• Research Findings and Conclusion
Moreover, rising incidence of Alagille syndrome, Cystinosis, Glomerulonephritis, Nephrotic
syndrome, thrombotic thrombocytopenic purpura (TTP), hemolytic uremic syndrome (HUS),
Interstitial nephritis, and others is expected to result in increasing demand for transplants.
Major market players are engaged in research and development activities and product launches
in order to introduce optimized dosage forms. For instance, in 2014, Rapamune, a formulation
developed by Pfizer, lost its exclusivity as an immunosuppressant for kidney transplant rejection
management in the U.S. However, in 2015, Rapamune became the first U.S. FDA approved
drug for treating Lymphangioleiomyomatosis (LAM) which is a rare progressive lung disease.
These factors are expected to support global sirolimus market growth over the forecast period.
Global Sirolimus Market Regional Insights
North America is expected to dominate the global sirolimus market due to an increasing
number of product approvals for preventing organ transplant rejection. For instance, one of the
major leading company Pfizer Inc. has carried out various clinical trial studies on sirolimus
1mg/2mg dose for different treatments such as graft rejection, kidney transplant, renal allograft
recipients, and renal transplants which has successfully completed phase IV in 2013.
Furthermore, growing demand for kidney transplants is expected to propel growth of the global
sirolimus market growth over the forecast period. According to the National Kidney Foundation,
2014 in U.S. data, every month approximately 3,000 patients were added to the kidney
transplant waiting list, and an estimated 13 people died each day while waiting for a life-saving
kidney transplant.
Global Sirolimus Market Restraints
Some of the factors restraining the global sirolimus market growth are the side effects
associated with sirolimus such as increased susceptibility to infection, malignancy,
hypertriglyceridemia, hypercholesterolemia, angioedema, and proteinuria. Administering
sirolimus to patients undergoing liver and lung transplants is generally avoided owing to side
effects such as hyperlipidemia and hepatic artery thrombosis.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/sirolimus-market-2842
Global Sirolimus Market Key Players
Some of the major players operating in the global sirolimus market include Pfizer Inc., Actiza,
Zydus Cadila Healthcare Ltd., Inc., Greenstone Llc., Biocon, Livzon NNR, and Intas
Pharmaceuticals Ltd.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Author
Alex Huge
Alex Huge369   documents Email
Document
Category
Health and Medicine
Views
1
File Size
109 KB
Tags
Sirolimus Market, market
1/--pages
Report inappropriate content